Navigation Links
PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
Date:8/30/2010

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that Anthony Maida, PhD has joined the Company as Vice President, Clinical Research. Dr. Maida will be responsible for leading PharmaNet's oncology team.

"Anthony's experience spans the drug development process. He has a unique strength in his well balanced expertise across strategic, operational and financial aspects of the business," said Dr. Robert Reekie, Chief Operating Officer and Senior Executive Vice President, Late Stage Development. "We are pleased to have Anthony as part of our outstanding oncology team."

Dr. Maida has more than twenty years of experience providing strategic, operational, and financial expertise to pharmaceutical companies that are focused primarily in the area of oncology.  Most recently, he ran his own consulting firm providing both pharmaceutical product development and capital raising capabilities to pharmaceutical firms, working with venture capital funds and investment banks. Prior to joining the pharmaceutical industry, Dr. Maida worked for Lockheed Corporation in a number of key financial roles.

Dr. Maida earned Bachelor of Arts degrees from the University of Santa Clara and San Jose State University, a Masters of Business Administration degree from the University of Santa Clara, a Masters degree in Toxicology from San Jose State University and a PhD in Tumor Immunology, from the University of California, Davis.  

About PharmaNet Development Group, Inc. PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  Contact: Anne-Marie HessPhone: (609) 951-6842E-mail: ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
2. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
3. Christopher Brennan Joins PharmaNet Development Group as General Counsel
4. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
5. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
6. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
7. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
8. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
11. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ -  Equicare Health Inc ., the ... recognized as one of the top 100 companies in ... listing that distinguishes the top digital health companies across ... step forward this year continually upgrading our product with ... base and team," says Len Grenier , CEO ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... Calif. , Nov. 17, 2016  AIC announces that it has just released ... in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a high ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):